An inflammation-based prognostic score (mGPS) predicts cancer survival independent of tumour site: a Glasgow Inflammation Outcome Study.
BACKGROUND
A selective combination of C-reactive protein and albumin (termed the modified Glasgow Prognostic Score, mGPS) has been shown to have prognostic value, independent of tumour stage, in lung, gastrointestinal and renal cancers. It is also of interest that liver function tests such as bilirubin, alkaline phosphatase and γ-glutamyl transferase, as well as serum calcium, have also been reported to predict cancer survival. The aim of the present study was to examine the relationship between an inflammation-based prognostic score (mGPS), biochemical parameters, tumour site and survival in a large cohort of patients with cancer.


METHODS
Patients (n=21,669) who had an incidental blood sample taken between 2000 and 2006 for C-reactive protein, albumin and calcium (and liver function tests where available) and a diagnosis of cancer were identified. Of this group 9608 patients who had an ongoing malignant process were studied (sampled within 2 years before diagnosis). Also a subgroup of 5397 sampled at the time of diagnosis (sampled within 2 months prior to diagnosis) were examined. Cancers were grouped by tumour site in accordance with International Classification of Diseases 10 (ICD 10).


RESULTS
On follow up, there were 6005 (63%) deaths of which 5122 (53%) were cancer deaths. The median time from blood sampling to diagnosis was 1.4 months. Increasing age, male gender and increasing deprivation was associated with a reduced 5-year overall and cancer-specific survival (all P<0.001). An elevated mGPS, adjusted calcium, bilirubin, alkaline phosphatase, aspartate transaminase, alanine transaminase and γ-glutamyl transferase were associated with a reduced 5-year overall and cancer-specific survival (independent of age, sex and deprivation in all patients sampled), as well as within the time of diagnosis subgroup (all P<0.001). An increasing mGPS was predictive of a reduced cancer-specific survival in all cancers (all P<0.001).


CONCLUSIONS
The results of the present study indicate that the mGPS is a powerful prognostic factor when compared with other biochemical parameters and independent of tumour site in patients with cancer.
University Department of Surgery, Faculty of Medicine-University of Glasgow, Royal Infirmary, Glasgow G31 2ER, UK. michael.j.proctor@gmail.com
M J
MJ
Proctor
D S
DS
Morrison
D
D
Talwar
S M
SM
Balmer
D S J
DS
O'Reilly
A K
AK
Foulis
P G
PG
Horgan
D C
DC
McMillan
D000328:Adult; D000368:Aged; D015331:Cohort Studies; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007249:Inflammation / Q000097:blood* / Q000175:diagnosis / Q000209:etiology / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging / Q000379:methods; D009369:Neoplasms / Q000150:complications / Q000175:diagnosis* / Q000401:mortality* / Q000473:pathology; D017063:Outcome Assessment, Health Care; D011379:Prognosis; D012107:Research Design; D016019:Survival Analysis
Cancer Causes Control. 2001 Dec;12(10):887-94
11808707
Br J Cancer. 2004 May 4;90(9):1704-6
15150622
Int J Colorectal Dis. 2007 Aug;22(8):881-6
17245566
Future Oncol. 2010 Jan;6(1):149-63
20021215
Curr Opin Clin Nutr Metab Care. 2009 May;12(3):223-6
19318937
Br J Cancer. 2010 Sep 7;103(6):870-6
20717110
Int J Cancer. 2009 Sep 15;125(6):1298-305
19431213
Lancet Oncol. 2004 Sep;5(9):568-74
15337487
Clin Chem. 2007 May;53(5):940-6
17384006
Ann Clin Biochem. 1986 Sep;23 ( Pt 5):533-7
3767289
Carcinogenesis. 2009 Jul;30(7):1073-81
19468060
Circulation. 2009 Nov 3;120(18):1784-92
19841303
Lancet. 2008 Mar 1;371(9614):771-83
18275997
Nature. 2002 Dec 19-26;420(6917):860-7
12490959
Proc Nutr Soc. 2008 Aug;67(3):257-62
18452641
J Clin Endocrinol Metab. 1996 Jun;81(6):2149-53
8964843
Clin Cancer Res. 2010 Jul 15;16(14):3754-9
20628028